A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines.

In recent years, there has been a growing interest between pharmaceutical companies and payers to implement Value Based Agreements (VBAs) based on clinical outcomes. VBAs are typically applied when access is not attained through “standard” value communication and negotiation, driven by uncertainties around the clinical evidence and / or financial impact of the drug in question. As more and more curative and transformative therapies such as gene therapies enter the market, payers are looking for innovative ways to pay for these next-generation medicines, which are often accompanied with an astronomical price tag.

Windrose Consulting Group collaborate with Cambridge University on a Executive education course on commercialization strategy

Ken Wilson announced as a Managing Partner.

Windrose Consulting Group is pleased to announce the addition of Matt Storer to the leadership team.  Matt joins as a Partner based in the London office, and will be leading the European Consulting Operations.